A Phase 3 interventional study of Nefecon and Placebo oral capsule in Primary IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Completed at 142 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Calliditas Therapeutics AB · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 16th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 21 in phase 3, and was the 20th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 22 · Phase 4 7
First in 1997; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 365 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 67 across the 67 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 73 have an industry lead sponsor. The 10 most frequent:
Calliditas Therapeutics AB is the lead sponsor of 11 studies on the registry; none are open to participants now.
Calliditas Therapeutics AB has 5 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. The study will consist of 2 parts, Part A and Part B. Part A will include a 9 month blinded Treatment Period, and a 3-month Follow up Period. Part B of the study will consist of a 12-month observational Follow up Period; no study drug will be administered during Part B. Part A and B will be blinded. Safety will be monitored by an independent Data Safety Monitoring Board.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nefecon 16 mg once daily by mouth for 9 months.
Drug: Nefecon
Placebo oral capsule once daily by mouth for 9 months.
Drug: Placebo oral capsule
Nefecon 16 mg for daily administration by mouth for 9 months.
Also known as: Budesonide modified released capsule
Placebo capsules for daily administration by mouth for 9 months.
Also known as: Placebo
Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline
Part A primary endpoint: The ratio of Urine Protein to Creatinine Ratio (UPCR) (based on 24-hour urine collections) at 9 months following the first dose of study drug compared to baseline. Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram
Time frame: 9 months
Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)
Part B Primary endpoint: Time-weighted average of estimated glomerular filtration rate (eGFR) recordings observed at each time point over 2 years. The eGFR (CKD-EPI) at 2 years (which must have been repeated to provide a second value obtained within 14 to 35 days) was the geometric mean of the 2 assessments.
Time frame: Up to 2 years and 1 month
Part A: Ratio of eGFR at 9 Months
Part A: Ratio of eGFR at 9 months compared to baseline calculated using the CKD-EPI formula.
Time frame: 9 months
Part A: Ratio of eGFR at 12 Months
Part A: Ratio of eGFR at 12 months compared to baseline calculated using the CKD-EPI formula.
Time frame: 12 months
Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months
Part A: Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline.
Time frame: 9 months
Part B: Time to 30% Reduction in eGFR
Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value. For clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.
Time frame: Over 2 years
Part B: Time to Receiving Rescue Medication.
Part B: Time from the first dose of study drug until receiving rescue medication. For clarity: Please note that the number of patients receiving rescue medication is presented with statistical analysis of the time to receiving rescue medication.
Time frame: Over 2 years
Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug
Time frame: 12, 18 and 24 months
Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug.
Time frame: 12 to 24 months
Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug;
Time frame: 12 to 24 months
Part B: Proportion of Patients Without Microhematuria
Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug
Time frame: 12 to 24 months
Part B: Short Form 36 (SF-36) Quality of Life Assessment at 9 Months.
Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.
Time frame: 9 months
Part B: Short Form 36 (SF-36) Quality of Life Assessment at 24 Months.
Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.
Time frame: 24 months
| Milestone | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Started | 182 | 182 |
| Completed | 175 | 174 |
| Not completed | 7 | 8 |
| Milestone | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Started | 175 | 174 |
| Completed | 161 | 165 |
| Not completed | 14 | 9 |
Part A primary endpoint: The ratio of Urine Protein to Creatinine Ratio (UPCR) (based on 24-hour urine collections) at 9 months following the first dose of study drug compared to baseline. Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram
| ratio | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline | 0.69 (0.61 to 0.79) | 0.95 (0.83 to 1.08) |
Part B Primary endpoint: Time-weighted average of estimated glomerular filtration rate (eGFR) recordings observed at each time point over 2 years. The eGFR (CKD-EPI) at 2 years (which must have been repeated to provide a second value obtained within 14 to 35 days) was the geometric mean of the 2 assessments.
| mL/min/1.73m2 | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR) | 0.96 (0.93 to 0.98) | 0.87 (0.84 to 0.89) |
Part A: Ratio of eGFR at 9 months compared to baseline calculated using the CKD-EPI formula.
| mL/min/1.73m2 | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part A: Ratio of eGFR at 9 Months | 1.00 (0.96 to 1.03) | 0.93 (0.90 to 0.96) |
Part A: Ratio of eGFR at 12 months compared to baseline calculated using the CKD-EPI formula.
| mL/min/1.73m2 | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part A: Ratio of eGFR at 12 Months | 0.97 (0.93 to 1.01) | 0.91 (0.88 to 0.95) |
Part A: Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline.
| g/gram | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months | 0.64 (0.55 to 0.75) | 0.93 (0.80 to 1.09) |
Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value. For clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.
| Participants | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Time to 30% Reduction in eGFR | 21 | 39 |
Part B: Time from the first dose of study drug until receiving rescue medication. For clarity: Please note that the number of patients receiving rescue medication is presented with statistical analysis of the time to receiving rescue medication.
| Participants | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Time to Receiving Rescue Medication. | 15 | 20 |
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug
| g/gram | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | 0.60 (0.54 to 0.66) | 1.01 (0.91 to 1.12) |
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug.
| g/gram | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | 0.52 (0.46 to 0.58) | 0.96 (0.86 to 1.08) |
Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug;
| mL/min/1.73m2 | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | 0.93 (0.90 to 0.96) | 0.84 (0.81 to 0.86) |
Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug
| Participants | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Part B: Proportion of Patients Without Microhematuria | 94 | 59 |
Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.
| Percentage of total possible score | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Bodily Pain | 54.353 ± 9.0306 | 54.659 ± 9.2387 |
| General Health | 47.058 ± 9.6373 | 48.014 ± 10.0120 |
| Mental Component Summary | 49.564 ± 9.2834 | 49.760 ± 8.8974 |
| Mental Health | 50.226 ± 8.9539 | 50.099 ± 8.8483 |
| Physical Component Summary | 52.257 ± 7.2188 | 53.732 ± 6.5876 |
| Physical Functioning | 52.722 ± 6.7370 | 54.276 ± 5.2243 |
| Role Emotional | 49.574 ± 9.4322 | 50.393 ± 8.3001 |
| Role Physical | 51.028 ± 8.0207 | 52.693 ± 6.6600 |
| Social Function | 50.941 ± 8.3606 | 51.707 ± 7.9259 |
| Vitality | 51.826 ± 10.0909 | 53.490 ± 9.3987 |
Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.
| Percentage of total possible score | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Bodily Pain | 53.385 ± 9.6352 | 53.208 ± 9.9811 |
| General Health | 47.038 ± 9.3450 | 47.214 ± 9.9564 |
| Mental Component Summary | 51.246 ± 8.1362 | 49.743 ± 10.2184 |
| Mental Health | 51.691 ± 8.2104 | 50.294 ± 10.0007 |
| Physical Component Summary | 51.443 ± 7.5200 | 51.993 ± 7.1783 |
| Physical Functioning | 52.665 ± 7.6364 | 53.059 ± 6.9006 |
| Role Emotional | 50.322 ± 8.4690 | 49.333 ± 10.0789 |
| Role Physical | 50.948 ± 7.8921 | 50.722 ± 8.8255 |
| Social Function | 51.949 ± 7.9677 | 51.471 ± 8.9304 |
| Vitality | 53.291 ± 8.8558 | 52.364 ± 10.0023 |
Collected over AEs were recorded from time of first dose of study treatment until 2 years after first dose (end of study). Treatment emergent AEs were those that occurred after the first dose of study drug until 14 days after the last dose, including tapering. SAEs were recorded from time of patient informed consent until end of study, i.e until 2 years and 3 months (including follow-up period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nefecon | 1/182 (0.5%) | 18/182 (9.9%) | 108/182 (59.3%) |
| Placebo Oral Capsule | 0/182 (0%) | 9/182 (4.9%) | 69/182 (37.9%) |
| Event | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Corona virus infectionInfections and infestations | 2/182 | 0/182 |
| PneumoniaInfections and infestations | 2/182 | 0/182 |
| Acute kidney injuryRenal and urinary disorders | 1/182 | 2/182 |
| Renal impairmentRenal and urinary disorders | 2/182 | 0/182 |
| HypertensionVascular disorders | 2/182 | 0/182 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/182 | 0/182 |
| Campylobacter colitisInfections and infestations | 0/182 | 1/182 |
| DiverticulitisInfections and infestations | 0/182 | 1/182 |
| ErysipelasInfections and infestations | 1/182 | 0/182 |
| Nephrotic syndromeRenal and urinary disorders | 1/182 | 0/182 |
| Event | Nefecon | Placebo Oral Capsule |
|---|---|---|
| Edema peripheralGeneral disorders | 28/182 | 7/182 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 22/182 | 7/182 |
| HypertensionVascular disorders | 21/182 | 6/182 |
| AcneSkin and subcutaneous tissue disorders | 20/182 | 2/182 |
| NasopharyngitisInfections and infestations | 17/182 | 19/182 |
| HeadacheGeneral disorders | 19/182 | 14/182 |
| DyspepsiaGastrointestinal disorders | 13/182 | 4/182 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/182 | 4/182 |
| NauseaGastrointestinal disorders | 8/182 | 12/182 |
| Upper respiratory tract infectionInfections and infestations | 10/182 | 10/182 |
Full analysis set - Global study
| Age, Continuous(years) | Nefecon | Placebo Oral Capsule | Total |
|---|---|---|---|
| Mean | 43.8 ± 10.78 | 41.6 ± 10.65 | 42.7 ± 10.76 |
| Sex: Female, Male(Participants) | Nefecon | Placebo Oral Capsule | Total |
|---|---|---|---|
| Female | 65 | 59 | 124 |
| Male | 117 | 123 | 240 |
| Race (NIH/OMB)(Participants) | Nefecon | Placebo Oral Capsule | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 43 | 40 | 83 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 138 | 137 | 275 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 5 | 6 |
| Baseline Urine protein to creatinine ratio (UPCR)(g/gram) | Nefecon | Placebo Oral Capsule | Total |
|---|---|---|---|
| Geometric mean | 1.300 (0.902 to 1.764) | 1.264 (0.877 to 1.737) | 1.282 (0.892 to 1.752) |
| Baseline Estimated glomerular filtration rate (eGFR)(ml/min/1.73 m2) | Nefecon | Placebo Oral Capsule | Total |
|---|---|---|---|
| Geometric mean | 56.006 (45.497 to 70.972) | 55.565 (45.957 to 67.735) | 55.785 (45.929 to 69.839) |
Showing the first 100 of 142 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Jul 2023, 58 months.
Results were first posted in Dec 2024, 1 year 4 months after primary completion.
Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 58 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide
Calliditas Therapeutics AB